For research use only. Not for therapeutic Use.
MRX-I（Cat No.:I008201）is an oxazolidinone-class antibiotic developed as a potent treatment option for bacterial infections, particularly those caused by drug-resistant gram-positive pathogens, including MRSA and Enterococcus species. It works by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, effectively stopping bacterial growth. Known for its promising safety profile and oral bioavailability, MRX-I is undergoing clinical trials as a potentially safer alternative to linezolid, aiming to reduce side effects like myelosuppression. MRX-I holds potential as a new-generation antibiotic for combating resistant bacterial infections.
| Catalog Number | I008201 |
| CAS Number | 1112968-42-9 |
| Synonyms | MRX-I; MRXI; MRX I;;(S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one |
| Molecular Formula | C18H15F3N4O4 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one |
| InChI | InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1 |
| InChIKey | SULYVXZZUMRQAX-NSHDSACASA-N |
| SMILES | C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3CC(OC3=O)CNC4=NOC=C4)F |
| Reference | </br>1:Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects. Eckburg PB, Ge Y, Hafkin B.Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02181-16. doi: 10.1128/AAC.02181-16. Print 2017 Apr. PMID: 28167545 </br>2:Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. Meng J, Zhong D, Li L, Yuan Z, Yuan H, Xie C, Zhou J, Li C, Gordeev MF, Liu J, Chen X.Drug Metab Dispos. 2015 May;43(5):646-59. doi: 10.1124/dmd.114.061747. Epub 2015 Feb 20. PMID: 25710940 Free Article</br>3:Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I. Huang Y, Xu Y, Liu S, Wang H, Xu X, Guo Q, Wu B, Gordeev MF, Wang W, Yuan Z, Wang M.Int J Antimicrob Agents. 2014 May;43(5):418-22. doi: 10.1016/j.ijantimicag.2014.02.008. Epub 2014 Mar 22. PMID: 24721233 </br>4:New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. Gordeev MF, Yuan ZY.J Med Chem. 2014 Jun 12;57(11):4487-97. doi: 10.1021/jm401931e. Epub 2014 Apr 16. Review. PMID: 24694071 </br>5:In vivo antibacterial activity of MRX-I, a new oxazolidinone. Li CR, Zhai QQ, Wang XK, Hu XX, Li GQ, Zhang WX, Pang J, Lu X, Yuan H, Gordeev MF, Chen LT, Yang XY, You XF.Antimicrob Agents Chemother. 2014;58(4):2418-21. doi: 10.1128/AAC.01526-13. Epub 2014 Jan 6. PMID: 24395231 Free PMC Article |
